Monograph Details
|
|
Endocrine System
> Diabetes
|
|
APIDRA |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Insulin glulisine (rDNA origin) 100 Units/mL; contains m-cresol. |
| Indications |
|
Diabetes. |
| Children |
|
Not recommended. |
| Adults |
|
Give SC, either by injection or by external infusion pump. Rotate injection sites. Give 15 minutes before meal or within 20 minutes after starting meal. Or, may give by IV under medical supervision in a clinical setting. Individualize; monitor and adjust as needed. |
| Contraindications |
|
During episodes of hypoglycemia. |
| Precautions |
|
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, and management of hypoglycemia. Monitor glucose, potassium levels (esp. by IV route). May need to adjust dose during infection, illness, stress, trauma, pregnancy. May need lesser dose with renal or hepatic dysfunction. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
See literature. Potentiated by ACE inhibitors, antidiabetic agents, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, sulfonamide antibiotics. Antagonized by corticosteroids, diuretics, sympathomimetics, glucagon, isoniazid, phenothiazines, somatropin, protease inhibitors, atypical antipsychotics, thyroid hormones, estrogens, progestogens. Variable effects with β-blockers, clonidine, lithium, alcohol. Do not mix with insulins other than NPH; draw insulin glulisine into syringe first, inject immediately after mixing. Do not dilute or mix with other insulins in pump. |
| Adverse Reactions |
|
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy. |
| How Supplied |
Vial (10mL)—1
Cartridges (3mL)—5 (use with OptiClik) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
